NIR II Laser-Triggered Photothermal Nanoplatform for Multimodal Imaging-Guided Synergistic Therapy toward Colon...

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Colon cancer presents significant global health challenges with limited treatment options.
• Phototherapy and gas therapy show promise but lack tumor specificity and penetration.
• Developing targeted, multimodal therapeutic strategies is crucial for effective colon cancer treatment.

Purpose of the Study:

• To develop a theranostic nanoplatform for imaging-guided synergistic colon cancer therapy.
• To enhance tumor targeting and therapeutic efficacy using a multifunctional agent.
• To evaluate the multimodal imaging and therapeutic capabilities of the nanoplatform.

Main Methods:

• Fabrication of a theranostic nanoplatform (Cet-CDs-SNO) incorporating Cetuximab, CDs, and SNO.
• Utilizing Cetuximab for tumor targeting and drug accumulation.
• Employing Ni²⁺/Mn²⁺ doped CDs for photothermal therapy (PTT), chemodynamic therapy (CDT), and multimodal imaging (PTI/MRI/FLI).
• Incorporating a nitric oxide (NO) donor (SNO) for gas therapy (GT) triggered by PTT.

Main Results:

• The Cet-CDs-SNO nanoplatform demonstrated excellent colon cancer-targeting ability in vitro and in vivo.
• Administration of the nanoplatform significantly inhibited colon cancer cell proliferation and tumor growth.
• The synergistic multimodal therapy showed no detectable cytotoxicity, indicating a favorable safety profile.

Conclusions:

• The developed theranostic nanoplatform offers a promising strategy for precise, imaging-guided colon cancer therapy.
• Multimodal imaging and synergistic therapeutic effects were achieved, overcoming limitations of existing treatments.
• This approach paves the way for advanced nanomedicine applications in oncology.